Interpharm(OTC) IPAH

Interpharm Holdings, Inc. specializes in the formulation, manufacturing, and commercialization of generic pharmaceuticals. Established in 1984, the company operates primarily from Hauppauge, New York, supplying a diverse range of clients including retail chains and healthcare organizations.

Products and Services

• Generic pharmaceuticals, including prescription and over-the-counter medications
• Formulation and manufacturing services tailored to client needs
• Distribution partnerships with major retail and wholesale networks

Growth Outlook

• Expansion into new markets is anticipated to drive revenue growth
• Increased demand for generic medications supports long-term sustainability
• Strategic partnerships may enhance distribution capabilities and market reach

Financial Highlights

• Recent quarterly revenue of $16.2 million indicates strong market presence
• Trailing twelve months (TTM) gross profit margin stands at 28.66%
• Current ratio of 1.05 suggests adequate short-term financial health

Interpharm Holdings, Inc. has established itself as a key player in the generic pharmaceuticals sector, focusing on both prescription and over-the-counter products. The company's commitment to quality and service has enabled it to build a robust client base, including significant retail chains and healthcare organizations. The growth outlook for Interpharm is promising, driven by an increasing demand for generic medications and potential market expansions. Recent financial performance reflects a solid revenue stream, with a notable gross profit margin that underscores operational efficiency. The current ratio indicates that the company is well-positioned to meet its short-term obligations, which is a positive sign for potential investors. Overall, Interpharm Holdings, Inc. presents an intriguing opportunity within the healthcare sector, particularly for those interested in the pharmaceutical industry. The combination of a strong product offering, growth potential, and stable financial metrics may appeal to investors looking for exposure in this market.